Abstract:
Methods for activating and/or reactivating a metal oxide surface for deposition, immobilizing, and/or growing a biological sample (e.g., an oligonucleotide, a polynucleotide, functionalized particle, a polymer, etc.) thereon are disclosed. The metal oxide surface (e.g., zirconium oxide) can be activated and/or reactivated by exposing the metal oxide surface to various activation and/or treatment protocols capable of enhancing a slide's activity relative to the activity of an untreated slide. The activation and/or treatment protocol can include subjecting the slide (or at least the metal oxide layer) to an oxygen plasma treatment and/or a peroxide solution for an amount of time sufficient to activate and/or reactivate the metal oxide surface. Activated sequencing slides capable of incorporation, for example, into various embodiments of a flow cell for use in NGS platforms are also disclosed herein.
Abstract:
The invention provides quinazoline compounds of the formula: wherein R 1 is halo; R 2 is H or halo; R 3 is a) C 1 -C 3 alkyl, optionally substituted by halo; or b) -(CH 2 ) n -morpholino, -(CH 2 ) n -piperidine, -(CH 2 ) n -piperazine, -(CH 2 ) n -piperazine-N(C 1 -C 3 alkyl), -(CH 2 ) n -pyrrolidine, or -(CH 2 ) n imidazole; n is 1 to 4; R 4 is -(CH 2 ) m -Het; Het is morpholine,piperidine, piperazine, piperazine-N(C 1 -C 3 alkyl), imidazole,pyrrolidine, azepane, 3,4-dihydro-2H-pyridine, or 3,6-dihydro-2H-pyridine, each optionally substituted by alkyl, halo, OH, NH 2 , NH(C 1 -C 3 alkyl) or N (C 1 -C 3 alkyl) 2 ; m is 1-3; and X is O, S or NH; or a pharmaceutically acceptable salt thereof, as well as processes and intermediate compounds for making them, useful pharmaceutical compositions and methods of using the compounds in the treatment of proliferative diseases.
Abstract:
This invention provides substituted Phenyl-(2-[1,3,4]thiadiazol-2-ylphenyl)-amine and (2-[1,3,4]Oxadiazol-2-yl-phenyl)phenyl-amine compounds which act as inhibitors of MAPKIERK Kinase ("MEK") enzymes and pharmaceutical compositions and methods for their use in immunomodulation and in the treatment and alleviation of inflammation, and proliferative diseases such as cancer and restenosis.
Abstract:
Methods, compositions, systems, apparatus, and kits are provided for depositing samples onto surfaces. The samples can include one or more particles, and the surface can include one or more reaction chambers. In some embodiments, the depositing can include the use of companion particles in combination with sample particles.
Abstract:
This invention provides phenyl-substituted pyrimidopyrimidines, dihydropyrimido-pyrimidines, pyridopyrimidines, naphthyridines,and pyridopyrazines of the general formula (I) that inhibit cyclin-dependent kinase and tyrosine kinase enzymes, methods and intermediate compounds for their synthesis,as well as pharmaceutical compositions and methods for their use in treating, inhibiting or preventing maladies associated with cell proliverative disorders, including angiogenesis, atherosclerosis, restenosis, and cancer.
Abstract:
Methods, compositions, systems, apparatus, and kits are provided for depositing samples onto surfaces. The samples can include one or more particles, and the surface can include one or more reaction chambers. In some embodiments, the depositing can include the use of companion particles in combination with sample particles.
Abstract:
The present invention provides compounds of Formula (I): f I wherein A, X, Q, Y, B, D, Z, and E have any of the values defined in the specification, and pharmaceutically acceptable salt thereof, that are useful as antidiabetic agents. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula I, process for preparing compounds of Formula I, and intermediates useful for preparing compounds of Formula I.
Abstract:
The present invention provides compounds of Formula (I): f I wherein A, X, Q, Y, B, D, Z, and E have any of the values defined in the specification, and pharmaceutically acceptable salt thereof, that are useful as antidiabetic agents. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula I, process for preparing compounds of Formula I, and intermediates useful for preparing compounds of Formula I.